Treatment relative effect with 95% CI; and degree of certainty (adaptated from GRADE).
method
| Treament |
Trials |
|
|
| clinical deterioration | clinical improvement | deaths | PCR-negative conversion |
| favipiravir | 6 | - | 0.60 [0.16; 2.26], 2 RCTs, I2=17%
inconclusive result | 1.12 [0.02; 62.74], 1 RCT, I2=0%
inconclusive result | 0.98 [0.21; 4.57], 2 RCTs, I2=32%
inconclusive result | |
| Renin-angiotensin-system-acting agents | 6 | OBS 0.73 [0.24; 2.24], 2 studies, I2=63%
inconclusive result | - | OBS 0.59 [0.38; 0.92], 4 studies, I2=0%
very low degree of certainty | - | |
| chloroquine and derivatives | 3 | - | - | 0.66 [0.01; 35.52], 1 RCT, I2=0%
inconclusive result | OBS 16.33 [2.80; 95.27], 1 study, I2=0%
low degree of certainty | |
| baloxavir marboxil | 1 | - | - | - | - | |
| hydroxychloroquine plus macrolides | 1 | - | - | OBS 1.14 [0.56; 2.32], 1 study, I2=0%
inconclusive result | - | |
| remdesivir | 1 | - | 1.32 [1.12; 1.55], 1 RCT, I2=0%
moderate degree of certainty | 0.70 [0.47; 1.04], 1 RCT, I2=0%
inconclusive result | - | |
| umifenovir (arbidol) | 1 | - | - | - | - | |
| ASC09/ritonavir | 0 | - | - | - | - | |
| azithromycin | 0 | - | - | - | - | |
| azvudine | 0 | - | - | - | - | |
| carrimycin | 0 | - | - | - | - | |
| danoprevir / ritonavir | 0 | - | - | - | - | |
| darunavir cobicistat | 0 | - | - | - | - | |
| darunavir/cobicistat plus chloroquine | 0 | - | - | - | - | |
| doxycycline | 0 | - | - | - | - | |
| fluvoxamine | 0 | - | - | - | - | |
| ivermectin | 0 | - | - | - | - | |
| leronlimab | 0 | - | - | - | - | |
| lopinavir / ritonavir plus ribavirin | 0 | - | - | - | - | |
| lopinavir/ritonavir | 0 | - | - | - | - | |
| lopinavir/ritonavir plus chloroquine | 0 | - | - | - | - | |
| lopinavir/ritonavir plus interferon ß-1a | 0 | - | - | - | - | |
| lopinavir/ritonavir, ribavirin and interferon beta-1b | 0 | - | - | - | - | |
| meplazumab | 0 | - | - | - | - | |
| nitazoxanide | 0 | - | - | - | - | |
| oseltamivir | 0 | - | - | - | - | |
| oseltamivir plus chloroquin | 0 | - | - | - | - | |
| ribavirin | 0 | - | - | - | - | |
| ritonavir | 0 | - | - | - | - | |
| sofosbuvir and daclatasvir | 0 | - | - | - | - | |
| tenofovir/emtricitabine | 0 | - | - | - | - | |
| tenofovir/emtricitabine plus hydroxychloroquine | 0 | - | - | - | - | |
| tranexamic acid | 0 | - | - | - | - | |
| triazavirin | 0 | - | - | - | - | |
